Clinical Trial Update: Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults. [Phase 2]

View source ↗

Summary

Phase 2 safety and tolerability study evaluating a lower dose of GSK2248761 in antiretroviral-treatment-naive HIV-1 infected adults completed with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• GSK2248761 (GSK2248761)

Snippet

Sponsor: ViiV Healthcare | Conditions: Infection, Human Immunodeficiency Virus | Phase 2 | Status: COMPLETED | Results posted: 2018-11-29